Optinose

Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps. Transaction…